Browsing Public Health by Subject "cyclin-dependent-kinase 4/6 inhibitors"
Now showing items 1-1 of 1
-
Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation
( MDPI , 2022 , Article)Palbociclib and ribociclib are indicated in the first-line treatment of hormonal-receptor-positive HER-2 negative (HR+/HER-2 negative) advanced breast cancer. Despite their clinical benefit, they can increase healthcare ...